SG11201606869TA - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents
Antimitotic amides for the treatment of cancer and proliferative disordersInfo
- Publication number
- SG11201606869TA SG11201606869TA SG11201606869TA SG11201606869TA SG11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA
- Authority
- SG
- Singapore
- Prior art keywords
- antimitotic
- amides
- cancer
- treatment
- proliferative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606869TA true SG11201606869TA (en) | 2016-09-29 |
Family
ID=52684675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606869TA SG11201606869TA (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
| SG10202000590SA SG10202000590SA (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202000590SA SG10202000590SA (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10016398B2 (zh) |
| EP (1) | EP3107909B1 (zh) |
| JP (1) | JP6506313B2 (zh) |
| KR (1) | KR102420508B1 (zh) |
| CN (2) | CN106068263A (zh) |
| AU (1) | AU2015218775C1 (zh) |
| BR (1) | BR112016019161B1 (zh) |
| CA (1) | CA2940237C (zh) |
| ES (1) | ES2893374T3 (zh) |
| IL (1) | IL247293B (zh) |
| MX (1) | MX2016010877A (zh) |
| RU (1) | RU2713179C2 (zh) |
| SG (2) | SG11201606869TA (zh) |
| WO (1) | WO2015127284A2 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| CN106068263A (zh) * | 2014-02-21 | 2016-11-02 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| CN1433413A (zh) * | 2000-06-05 | 2003-07-30 | 东亚制药株式会社 | 新的噁唑烷酮衍生物及其制备方法 |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| WO2006002896A1 (en) * | 2004-06-30 | 2006-01-12 | Novartis Ag | Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors |
| US20090156646A1 (en) * | 2005-08-11 | 2009-06-18 | Takeda Pharmaceutical Company Limited | Pyridylphenol compound and use thereof |
| AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| JP2010510191A (ja) | 2006-11-17 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス剤としての２−カルボキシチオフェン誘導体 |
| JP2010523639A (ja) * | 2007-04-12 | 2010-07-15 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬化合物 |
| AU2009300316A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| EA020526B1 (ru) * | 2009-09-11 | 2014-11-28 | Амген Инк. | Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака |
| JP6112486B2 (ja) * | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US20130063385A1 (en) * | 2010-05-14 | 2013-03-14 | Sharp Kabushiki Kaisha | Portable information terminal and method for controlling same |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| WO2012100135A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Picolinamide inhibitors of kinases |
| EP2673264A1 (en) * | 2011-02-10 | 2013-12-18 | Syngenta Participations AG | Microbiocidal pyrazole derivatives |
| CA2834928C (en) * | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| JP2014532656A (ja) * | 2011-10-28 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための化合物 |
| CN106068263A (zh) * | 2014-02-21 | 2016-11-02 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
-
2015
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en active Application Filing
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 CN CN202210190090.XA patent/CN114634483A/zh active Pending
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
- 2015-02-20 MX MX2016010877A patent/MX2016010877A/es unknown
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active IP Right Grant
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US20220008395A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015218775B2 (en) | 2019-06-20 |
| WO2015127284A2 (en) | 2015-08-27 |
| RU2016135555A3 (zh) | 2018-10-05 |
| AU2015218775C1 (en) | 2020-01-16 |
| US20200397758A1 (en) | 2020-12-24 |
| RU2016135555A (ru) | 2018-03-28 |
| BR112016019161B1 (pt) | 2022-12-20 |
| US20220008395A1 (en) | 2022-01-13 |
| ES2893374T3 (es) | 2022-02-08 |
| KR20160116009A (ko) | 2016-10-06 |
| IL247293B (en) | 2021-01-31 |
| US11129813B2 (en) | 2021-09-28 |
| KR102420508B1 (ko) | 2022-07-13 |
| EP3107909B1 (en) | 2021-07-14 |
| CA2940237A1 (en) | 2015-08-27 |
| JP2017506267A (ja) | 2017-03-02 |
| RU2713179C2 (ru) | 2020-02-04 |
| CA2940237C (en) | 2023-03-07 |
| SG10202000590SA (en) | 2020-03-30 |
| JP6506313B2 (ja) | 2019-04-24 |
| MX2016010877A (es) | 2017-05-04 |
| CN114634483A (zh) | 2022-06-17 |
| US10016398B2 (en) | 2018-07-10 |
| EP3107909A2 (en) | 2016-12-28 |
| AU2015218775A1 (en) | 2016-08-25 |
| US10772872B2 (en) | 2020-09-15 |
| BR112016019161A2 (zh) | 2017-08-15 |
| US20180325871A1 (en) | 2018-11-15 |
| US20170172984A1 (en) | 2017-06-22 |
| CN106068263A (zh) | 2016-11-02 |
| WO2015127284A3 (en) | 2015-10-15 |
| IL247293A0 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| IL262416A (en) | Materials and methods for the treatment of hemoglobin diseases | |
| SG11201706766WA (en) | Materials and methods for treatment of hemoglobinopathies | |
| SG11201703193XA (en) | Treatment for depression and depressive disorders | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| HUE053654T2 (hu) | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére | |
| HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
| GB201506851D0 (en) | Apparatus and method for providing hyperthermia therapy | |
| EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
| IL251904B (en) | Epilimod for use in the treatment of melanoma | |
| IL247293A0 (en) | Antimitotic amides for the treatment of cancer and proliferative diseases | |
| EP3154616A4 (en) | Methods and apparatus for treatment of respiratory disorders | |
| EP3302207A4 (en) | APPARATUSES AND METHODS FOR SURFACE TREATMENT | |
| HK1245778A1 (zh) | 用於治療原發性癌症和癌症擴散的小分子 | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| AU2016905121A0 (en) | Methods of Treating Proliferative Disorders | |
| PL3190212T3 (pl) | Urządzenie do obróbki powierzchniowej materiału ciągłego i jego zastosowanie | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| GB201414904D0 (en) | Materials and methods for treating cancer |